Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.
Jakobsen NA. et al, (2024), Cell Stem Cell, 31, 1127 - 1144.e17
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Freeman SD. et al, (2023), Blood, 142, 1697 - 1707
GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells.
Turkalj S. et al, (2023), Cell Stem Cell, 30, 722 - 740.e11
Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).
Sternberg A. et al, (2022), Br J Haematol, 199, 222 - 229
Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy.
Symeonidou V. et al, (2022), EJHaem, 3, 794 - 803
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
Loke J. et al, (2022), Br J Haematol, 196, 368 - 373
Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia
Sweeney C. et al, (2022), BLOOD, 140, 1576 - 1578
Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2-Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study
Chatzikyriakou P. et al, (2022), BLOOD, 140, 3414 - 3415
Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation
Jakobsen NA. et al, (2022), BLOOD, 140, 2227 - 2228
Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.
Cruz Hernandez D. et al, (2020), Blood, 136, 1460 - 1465
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.
Hanekamp D. et al, (2020), Br J Haematol, 190, 891 - 900
Mechanisms of Response and Resistance to AML Therapies.
Stoilova B. et al, (2020), Clin Lymphoma Myeloma Leuk, 20 Suppl 1
Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features.
Roos-Weil D. et al, (2020), Blood, 136, 585 - 595
A shared somatic translocation involving CUX1 in monozygotic twins as an early driver of AMKL in Down syndrome.
Bache I. et al, (2020), Blood Cancer J, 10
Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
Labuhn M. et al, (2019), Cancer Cell, 36
Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
Labuhn M. et al, (2019), Cancer Cell, 36, 123 - 138.e10
A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.
Roos-Weil D. et al, (2019), Cancer Discov, 9, 796 - 811
Most haematological abnormalities in neonates with Down syndrome are transient but dysplastic myelopoiesis persists throughout early childhood
Hanssen L. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 106 - 106